Company Product Description Indication Status
Algernon Pharmaceuticals Inc., of Vancouver, British Columbia NP-120 (repurposed ifenprodil) NMDA receptor epsilon 2 subunit inhibitor COVID-19 infection Request for ethics approval of multinational phase IIb/III study submitted in Australia 
Blueprint Medicines Corp., of Cambridge, Mass. Avapritinib (Ayvakit) KIT tyrosine kinase inhibitor Gastrointestinal stromal tumor FDA issued CRL for NDA seeking to treat adults with unresectable or metastatic fourth-line disease; company halting development in GIST indications other than already approved PDGFRA exon 18 mutant disease
Bristol Myers Squibb Co., of New York Pomalyst (pomalidomide) TNF-alpha inhibitor Kaposi sarcoma FDA granted accelerated approval to treat AIDS-related disease resistant to HAART or disease in individuals who are HIV-negative
Can-Fite Biopharma Ltd., of Petach Tikva, Israel Piclidenoson A3 adenosine receptor agonist COVID-19 (moderate to severe symptoms) Filed a pre-IND meeting request with the FDA 
Clovis Oncology Inc., of Boulder, Colo. Rubraca (rucaparib) PARP inhibitor Metastatic castration-resistant prostate cancer Approved by FDA under accelerated approval for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated disease who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
Deciphera Pharmaceuticals Inc., of Waltham, Mass. Qinlock (ripretinib) Kinase inhibitor Advanced gastrointestinal stromal tumor FDA approved as fourth-line treatment, indicated for adults who have received prior treatment with 3 or more kinase inhibitor therapies, including imatinib
Kancera AB, of Stockholm KAND-567 Fractalkine blocker COVID-19 Submitted an application to the Swedish Medicines Agency for permission to conduct a phase II study
Leading Biosciences Inc., of Carlsbad, Calif. LB-1148 (tranexamic acid) Serine protease inhibitor Pulmonary dysfunction associated with COVID-19 pneumonia FDA cleared its IND application for a phase II study 
Neuraptive Therapeutics Inc., of Philadelphia NTX-001 Drug-device combination Peripheral nerve injuries FDA granted fast track designation
Seelos Therapeutics Inc., of New York SLS-005 (trehalose) Transcription factor EB stimulator Sanfilippo syndrome Granted a rare pediatric disease designation by the FDA

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments